Bryn Mawr Trust CO Ultragenyx Pharmaceutical Inc. Transaction History
Bryn Mawr Trust CO
- $5.44 Billion
- Q4 2024
A detailed history of Bryn Mawr Trust CO transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 470 shares of RARE stock, worth $19,725. This represents 0.0% of its overall portfolio holdings.
Number of Shares
470
Previous 1,489
68.44%
Holding current value
$19,725
Previous $82,000
76.83%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RARE
# of Institutions
344Shares Held
86.6MCall Options Held
675KPut Options Held
846K-
Vanguard Group Inc Valley Forge, PA10MShares$421 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$235 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.3MShares$180 Million0.57% of portfolio
-
State Street Corp Boston, MA2.72MShares$114 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.51MShares$105 Million0.01% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.94B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...